End Brain Cancer Initiative - the Chris Elliott Fund

Directions Website

End Brain Cancer Initiative - the Chris Elliott Fund We are a non-profit providing national brain tumor patient support since 2002. Our goal is to end br

Our Mission

End Brain Cancer is furiously committed to finding a cure for brain cancer and to bringing HOPE to the lives of patients and their families. Everything we do is directed towards our ultimate mission, which is to EndBrainCancer within our lifetimes. We are unique in the one-on-one personalized support we offer to brain tumor patients and their families. Additionally, we:
Provide patients with IMMEDIATE ACCESS to advanced treatment options, specialists & comprehensive support programs

Provide support & guidance concerning the DAY-TO-DAY needs of patients and their caregivers. Educate the general public on matters related to brain tumors and brain cancer

Advocate on issues of national public health policy impacting the lives and welfare of brain tumor patients/brain cancer patients

Our ultimate goal is to put ourselves out of business when a cure is found for brain cancer and our services are no longer needed. Please contact us at [email protected] or call us at 1-800-574-5703 for more information. For a little bit about what we do visit our patient services page.

💚 Your Story Matters. Your Experience Can Make a Difference.When it comes to glioblastoma, patients and caregivers bring...
10/16/2026

💚 Your Story Matters. Your Experience Can Make a Difference.
When it comes to glioblastoma, patients and caregivers bring something invaluable to the conversation: real-world experience.

Did you know that patient advisory boards help researchers and healthcare organizations better understand the challenges people face throughout their treatment journeys?

From navigating a diagnosis to making treatment decisions and managing everyday life, your experiences can help identify unmet needs and inform future patient-centered research.

🧠 We want to hear from you!
End Brain Cancer Initiative (EBCI) is seeking 5 glioblastoma patients or caregivers to participate in an upcoming virtual advisory board.

✅ $400 compensation for participation
✅ Two 2-hour virtual sessions
✅ Tentatively scheduled for late October or early November 2026
✅ U.S. residents only
✅ Participants must not be healthcare providers

Patients must have an IDH-wildtype glioblastoma diagnosis and have undergone at least one line of therapy. Caregivers of glioblastoma patients are also encouraged to inquire.

💚 Your voice matters. Your perspective matters. And your story deserves to be heard.

👉 Interested in participating? https://monkeylink.co/6d5e37
Please share this opportunity with anyone in the glioblastoma community who may qualify!

10/16/2026

💚 Your Experience Matters. Your Voice Deserves to Be Heard.
End Brain Cancer Initiative (EBCI) is seeking 5 glioblastoma patients or caregivers to participate in a paid virtual advisory board.

This is an opportunity to share your personal experiences, challenges, and perspectives in a supportive discussion.

💚 Receive $400 for participating
💻 Two 2-hour virtual sessions
📅 Tentatively late October or early November 2026
🇺🇸 U.S. residents only

Interested in learning more? Contact EBCI for eligibility information and next steps. https://monkeylink.co/6d5e37

Eric Peltzer and Sherry Gensemer are both glioblastoma (GBM) brain cancer patients who use the Optune Gio device. In the...
10/16/2026

Eric Peltzer and Sherry Gensemer are both glioblastoma (GBM) brain cancer patients who use the Optune Gio device. In their presentations during the End Brain Cancer Initiative's free educational webinar on November 6th, they will share their patient stories, as well as tips and tricks they have learned for using the Optune Gio device.

Register now to get all of the information to join this free online event, designed to provide caregivers with valuable tools, tips, and resources: https://monkeylink.co/d4aef9

Thank you to Novocure and others for sponsoring this patient disease education event.

Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.SIGMA ...
10/15/2026

Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.

SIGMA is a Phase 3 study evaluating investigational safusidenib in IDH1-Mutant Glioma.

Learn more: https://monkeylink.co/2f967f

A Phase 2 clinical trial of Immune12 is currently enrolling patients with glioblastoma (GBM) brain cancer to support mar...
10/12/2026

A Phase 2 clinical trial of Immune12 is currently enrolling patients with glioblastoma (GBM) brain cancer to support marketing authorization in Australia (registered with the Australian New Zealand Clinical Trials Registry, ANZCTR).

The trial is led by Chief Principal Investigator Dr. Janet Schloss, PhD, ND, and plans to enroll approximately 60 participants.

Trial locations are in Australia at Chris O’Brien Lifehouse in Camperdown, New South Wales and Greenslopes Private Hospital in Greenslopes, Queensland. Trial participants MUST be Australian residents.

Request more information about this trial by filling out EBCI's interest form here: https://monkeylink.co/18c24b

The End Brain Cancer Initiative (EBCI) has been working with the National Brain Tumor Society (NBTS) and others to advoc...
10/09/2026

The End Brain Cancer Initiative (EBCI) has been working with the National Brain Tumor Society (NBTS) and others to advocate for grant funding for the Pediatric Early Phase Clinical Trials Network (PEP-CTN).

We and the other signers recently sent an official letter strongly urging the National Cancer Institute (NCI) to fully fund the PEP-CTN at its requested $7.5 million level for Grant Year 8 and provide sustained multi-year funding to ensure long-term stability and growth in order to help address the URGENT need for innovative treatments for children with brain tumors.

Anthony Letai, Director of the National Cancer Institute (NCI), replied to the funding request letter saying that, "NCI intends to continue supporting the PEP-CTN as it fully assumes and transitions the historic PBTC portfolio across Grant Years 8 through 10. This multi-year funding commitment will support clinical trial operations, scientific leadership, and imaging capabilities, administrative modernization, and new approaches, including the use of artificial intelligence, to improve trial efficiency and patient accrual."

This type of advocacy is crucial for the advancement of brain tumor/brain cancer treatments, research, and patient access. However, financial support for this type of EBCI Advocacy work is ONLY funded by individual donors.

Give today to help the End Brain Cancer Initiative continue advocating on behalf of patients, caregivers, and families: https://monkeylink.co/724487

💚 It's National DAF Day! Give Hope. Make an Impact.Your charitable giving can help change the journey for patients and f...
10/09/2026

💚 It's National DAF Day! Give Hope. Make an Impact.
Your charitable giving can help change the journey for patients and families facing brain cancer.

If you have a Donor-Advised Fund, consider recommending a grant to the End Brain Cancer Initiative (EBCI).

Your support helps advance our mission to empower patients and caregivers through education, advocacy, and access to critical information about treatment options.
https://monkeylink.co/434b98

✨ One grant. Meaningful impact. Hope for families facing brain cancer.

GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, announced the publicati...
10/08/2026

GT Medical Technologies, a company focused on improving the lives of patients with brain tumors, announced the publication of the results of the randomized, multicenter ROADS trial (NCT04365374) as a Rapid Communication in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO).

The End Brain Cancer Initiative was proud to partner with GT Medical on the ROADS trial to increase patient access through education, awareness, outreach, and enrollment support.

The data demonstrate that patients with newly diagnosed operable brain metastases treated with tumor removal surgery and GammaTile® cesium-131 collagen tile-based radiation therapy (TBRT) experienced lower local tumor recurrence and lived significantly longer compared to the standard-of-care approach of surgery followed by post-operative stereotactic radiation therapy (SRT).

In the manuscript's conclusion, the study authors state that GammaTile® should be considered a standard-of-care option for patients with newly diagnosed brain metastases.

Read the press release here: https://monkeylink.co/2a1652

💚 Tomorrow is National DAF Day!Did you know that a Donor-Advised Fund (DAF) can be a powerful way to support causes that...
10/08/2026

💚 Tomorrow is National DAF Day!
Did you know that a Donor-Advised Fund (DAF) can be a powerful way to support causes that matter most to you?

A DAF is a charitable giving account that allows donors to recommend grants to eligible nonprofit organizations.

If you have a DAF, consider recommending a grant to the End Brain Cancer Initiative (EBCI).

Your generosity can help us continue connecting brain cancer patients and caregivers with education, resources, and information about treatment options and clinical trials.
https://monkeylink.co/434b98
💚 Together, we can make a difference.

Address

Redmond, WA

Website

Alerts

Be the first to know and let us send you an email when End Brain Cancer Initiative - the Chris Elliott Fund posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share